Company Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Ram Aiyar |
Contact Details
Address: 60 First Street, 2nd Floor Cambridge, Massachusetts 02141 United States | |
| Phone | 617 468 1999 |
| Website | korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 1703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2026 | 144 | Filing |
| Jun 16, 2026 | 144 | Filing |
| Jun 16, 2026 | 144 | Filing |
| Jun 16, 2026 | 144 | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| May 29, 2026 | 144 | Filing |
| May 19, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 424B3 | Prospectus |
| May 7, 2026 | 10-Q | Quarterly Report |